EA200700934A1 - Производные пиримидина и их применение в качестве модуляторов cb2 - Google Patents
Производные пиримидина и их применение в качестве модуляторов cb2Info
- Publication number
- EA200700934A1 EA200700934A1 EA200700934A EA200700934A EA200700934A1 EA 200700934 A1 EA200700934 A1 EA 200700934A1 EA 200700934 A EA200700934 A EA 200700934A EA 200700934 A EA200700934 A EA 200700934A EA 200700934 A1 EA200700934 A1 EA 200700934A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pyrimidine derivatives
- modulators
- application
- diseases
- indirectly
- Prior art date
Links
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108050007331 Cannabinoid receptor Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Данное изобретение относится к новым производным пиримидина, фармацевтическим композициям, содержащим такие соединения, и их применению при лечении болезней, в частности боли, вызванных непосредственно или косвенно повышением или понижением активности каннабиноидных рецепторов.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0219501A GB0219501D0 (en) | 2002-08-21 | 2002-08-21 | Compounds |
GB0309326A GB0309326D0 (en) | 2003-04-24 | 2003-04-24 | Compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200700934A1 true EA200700934A1 (ru) | 2007-08-31 |
EA012703B1 EA012703B1 (ru) | 2009-12-30 |
Family
ID=31948030
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200500392A EA010130B1 (ru) | 2002-08-21 | 2003-08-19 | (тетрагидропиран-4-илметил)амид 2-(2,4-дихлорфениламино)-4-трифторметилпиримидин-5-карбоновой кислоты, фармацевтическая композиция, содержащая его, и способ лечения человека или животного, страдающего от состояния, которое опосредуется активностью каннабиноидных рецепторов 2 |
EA200700934A EA012703B1 (ru) | 2002-08-21 | 2003-08-19 | Производные пиримидина и их применение в качестве модуляторов cb2 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200500392A EA010130B1 (ru) | 2002-08-21 | 2003-08-19 | (тетрагидропиран-4-илметил)амид 2-(2,4-дихлорфениламино)-4-трифторметилпиримидин-5-карбоновой кислоты, фармацевтическая композиция, содержащая его, и способ лечения человека или животного, страдающего от состояния, которое опосредуется активностью каннабиноидных рецепторов 2 |
Country Status (35)
Country | Link |
---|---|
US (2) | US7635701B2 (ru) |
EP (2) | EP1878725B1 (ru) |
JP (1) | JP4583174B2 (ru) |
KR (1) | KR20050058367A (ru) |
CN (1) | CN100351239C (ru) |
AP (1) | AP2005003219A0 (ru) |
AR (1) | AR041016A1 (ru) |
AT (2) | ATE377591T1 (ru) |
AU (1) | AU2003264076B2 (ru) |
BR (1) | BR0313676A (ru) |
CA (1) | CA2495880C (ru) |
CY (1) | CY1107871T1 (ru) |
DE (2) | DE60317348T2 (ru) |
DK (1) | DK1539712T3 (ru) |
EA (2) | EA010130B1 (ru) |
EC (1) | ECSP055613A (ru) |
ES (1) | ES2295682T3 (ru) |
HK (1) | HK1079193A1 (ru) |
IL (2) | IL166552A0 (ru) |
IS (1) | IS7749A (ru) |
MA (1) | MA27428A1 (ru) |
MX (1) | MXPA05001960A (ru) |
MY (1) | MY137053A (ru) |
NO (1) | NO20051451D0 (ru) |
NZ (1) | NZ537886A (ru) |
OA (1) | OA12910A (ru) |
PE (1) | PE20040898A1 (ru) |
PL (1) | PL376047A1 (ru) |
PT (1) | PT1539712E (ru) |
SI (1) | SI1539712T1 (ru) |
TW (1) | TW200410946A (ru) |
UA (1) | UA83194C2 (ru) |
UY (1) | UY27939A1 (ru) |
WO (1) | WO2004018433A1 (ru) |
ZA (1) | ZA200500913B (ru) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY27939A1 (es) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
AU2003275242B2 (en) | 2002-09-27 | 2010-03-04 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
GB0402356D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
GB0402355D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
EP1809614B1 (en) | 2004-04-08 | 2014-05-07 | TargeGen, Inc. | Benzotriazine inhibitors of kinases |
EP1799656A4 (en) | 2004-08-25 | 2009-09-02 | Targegen Inc | HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
GB0517188D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
CN103626742B (zh) | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
CA2632030A1 (en) | 2005-12-15 | 2007-06-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
EP2007707A1 (en) * | 2006-04-07 | 2008-12-31 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
WO2008014199A2 (en) | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 receptor |
US8236841B2 (en) | 2006-09-13 | 2012-08-07 | Kyowa Hakko Kirin Co., Ltd. | Fused heterocycle derivative |
AU2007300295A1 (en) | 2006-09-25 | 2008-04-03 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
AU2007304363B2 (en) * | 2006-10-04 | 2013-01-17 | F. Hoffmann-La Roche Ag | Pyrazine-2-carboxamide derivatives as CB2 receptor modulators |
US7928103B2 (en) | 2006-10-17 | 2011-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
EP2139852A1 (en) | 2006-12-19 | 2010-01-06 | Pharmos Corporation | Sulfonamide derivatives with therapeutic indications |
GB0705803D0 (en) * | 2007-03-28 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
CA2704475A1 (en) * | 2007-11-06 | 2009-05-14 | Emory University | Methods of identifying improved nmda receptor antagonists |
EP2217565B1 (en) | 2007-11-07 | 2013-05-22 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
WO2010005782A1 (en) | 2008-07-10 | 2010-01-14 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the cb2 receptor |
NZ591111A (en) | 2008-09-25 | 2013-08-30 | Boehringer Ingelheim Int | Sulfonyl compounds which selectively modulate the cb2 receptor |
TW201031649A (en) | 2008-12-02 | 2010-09-01 | Organon Nv | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives |
TW201031650A (en) * | 2008-12-02 | 2010-09-01 | Organon Nv | 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione |
JPWO2010113834A1 (ja) | 2009-03-30 | 2012-10-11 | アステラス製薬株式会社 | ピリミジン化合物 |
US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
EP2443107B1 (en) | 2009-06-16 | 2018-08-08 | Boehringer Ingelheim International GmbH | Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor |
EP2480544A1 (en) | 2009-09-22 | 2012-08-01 | Boehringer Ingelheim International GmbH | Compounds which selectively modulate the cb2 receptor |
WO2011088015A1 (en) | 2010-01-15 | 2011-07-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
US8329735B2 (en) | 2010-03-05 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the CB2 receptor |
US8846936B2 (en) | 2010-07-22 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the CB2 receptor |
TWI482622B (zh) | 2010-07-29 | 2015-05-01 | Astellas Pharma Inc | Shrinkage pyridine compounds |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
WO2014143661A1 (en) * | 2013-03-15 | 2014-09-18 | Waterfi, Llc | Method for water-proofing elecronic components |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
CN106414456B (zh) * | 2013-10-23 | 2018-12-14 | 中央研究院 | 用于预防和治疗神经退行性疾病和疼痛的化合物 |
WO2017185038A1 (en) | 2016-04-22 | 2017-10-26 | Receptor Life Sciences | Fast-acting plant-based medicinal compounds and nutritional supplements |
EA201892396A1 (ru) | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5518A (en) | 1848-04-18 | Geaijst-drieb | ||
US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
FR2634376B1 (fr) | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
US5112820A (en) * | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
HUT63941A (en) * | 1992-05-15 | 1993-11-29 | Hoechst Ag | Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same |
CA2118517C (en) | 1992-06-10 | 2003-10-14 | Gary G. Liversidge | Surface modified nsaid nanoparticles |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
US5302401A (en) | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
US5340564A (en) | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
AU692484B2 (en) * | 1993-10-12 | 1998-06-11 | Du Pont Pharmaceuticals Company | 1N-alkyl-N-arylpyrimidinamines and derivatives thereof |
US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
US5587143A (en) | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
US5571536A (en) | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5560931A (en) | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5503723A (en) | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
US5622938A (en) | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
US5518738A (en) | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
CZ293211B6 (cs) | 1995-02-13 | 2004-03-17 | G. D. Searle & Co. Corporate Patent Dept. | Substituované izoxazoly pro léčení zánětů |
US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
CA2230894A1 (en) * | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
US5811428A (en) | 1995-12-18 | 1998-09-22 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
UA57002C2 (ru) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Производное (метилсульфонил)фенил-2-(5н)-фуранона, фармацевтическая композиция и способ лечения |
EP0855906B1 (en) | 1995-10-17 | 2008-02-20 | Jagotec AG | Insoluble drug delivery |
FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
EP0892791B1 (en) | 1996-04-12 | 2003-03-05 | G.D. Searle & Co. | N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPYLAMIDE and its SODIUMSALT AS PRODRUGS OF COX-2 INHIBITORS |
PL187848B1 (pl) | 1996-07-18 | 2004-10-29 | Merck Frosst Canada Inc | Podstawione pirydyny, kompozycja farmaceutyczna, podstawione pirydyny jako selektywne inhibitory cyklooksygenazy-2 oraz zastosowanie podstawionych pirydyn |
WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
KR100382619B1 (ko) | 1997-09-05 | 2003-05-09 | 글락소 그룹 리미티드 | 2,3-디아릴-피라졸로[1,5-b]피리다진 유도체, 그의 제조방법 및 시클로옥시게나제 2(cox-2) 억제제로서의 용도 |
US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
AU755993C (en) | 1998-06-19 | 2003-10-30 | Skyepharma Canada Inc. | Processes to generate submicron particles of water-insoluble compounds |
WO2000018374A1 (en) | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
KR20010075673A (ko) | 1998-11-03 | 2001-08-09 | 그레이엄 브레레톤, 레슬리 에드워즈 | 선택적 cox-2 억제제로서의 피라졸로피리딘 유도체 |
US6180136B1 (en) | 1998-11-10 | 2001-01-30 | Idexx Laboratories, Inc. | Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use |
CN1213733C (zh) | 1998-11-20 | 2005-08-10 | 斯凯伊药品加拿大公司 | 制备稳定的不溶性微粒的悬浮液的方法 |
US6025683A (en) | 1998-12-23 | 2000-02-15 | Stryker Corporation | Motor control circuit for regulating a D.C. motor |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
AU2661400A (en) | 1999-02-27 | 2000-09-21 | Glaxo Group Limited | Pyrazolopyridines |
GB9927844D0 (en) * | 1999-11-26 | 2000-01-26 | Glaxo Group Ltd | Chemical compounds |
BR0008060A (pt) | 1999-12-08 | 2002-02-05 | Pharmacia Corp | Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica |
GB0003224D0 (en) * | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
CA2413330A1 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
BR0113628A (pt) | 2000-08-31 | 2003-07-01 | Hoffmann La Roche | 7-oxo-piridopirimidinas como inibidores de uma proliferação celular |
GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
JP2005503998A (ja) | 2001-01-29 | 2005-02-10 | ユニバーシティ オブ コネチカット | 受容体選択性のカンナビミメティックアミノアルキルインドール |
US7507767B2 (en) | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
EP1361879A1 (en) | 2001-02-20 | 2003-11-19 | Bristol-Myers Squibb Company | 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators |
FR2839718B1 (fr) | 2002-05-17 | 2004-06-25 | Sanofi Synthelabo | Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant |
JP2005533809A (ja) | 2002-06-19 | 2005-11-10 | シェーリング コーポレイション | カンナビノイドレセプタアゴニスト |
US7449456B2 (en) | 2002-06-28 | 2008-11-11 | Astellas Pharma, Inc. | Diaminopyrimidinecarboxamide derivative |
UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
ATE340785T1 (de) | 2002-08-21 | 2006-10-15 | Glaxo Group Ltd | 2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren |
GB0222493D0 (en) | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
AU2003275242B2 (en) | 2002-09-27 | 2010-03-04 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
GB0222495D0 (en) | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
-
2003
- 2003-08-14 UY UY27939A patent/UY27939A1/es not_active Application Discontinuation
- 2003-08-19 PL PL03376047A patent/PL376047A1/xx not_active Application Discontinuation
- 2003-08-19 AU AU2003264076A patent/AU2003264076B2/en not_active Ceased
- 2003-08-19 NZ NZ537886A patent/NZ537886A/en unknown
- 2003-08-19 US US10/524,470 patent/US7635701B2/en not_active Expired - Fee Related
- 2003-08-19 TW TW092122692A patent/TW200410946A/zh unknown
- 2003-08-19 DE DE60317348T patent/DE60317348T2/de not_active Expired - Lifetime
- 2003-08-19 CN CNB038241293A patent/CN100351239C/zh not_active Expired - Fee Related
- 2003-08-19 CA CA2495880A patent/CA2495880C/en not_active Expired - Fee Related
- 2003-08-19 MX MXPA05001960A patent/MXPA05001960A/es active IP Right Grant
- 2003-08-19 AP AP2005003219A patent/AP2005003219A0/xx unknown
- 2003-08-19 UA UAA200501583A patent/UA83194C2/ru unknown
- 2003-08-19 EP EP07119063A patent/EP1878725B1/en not_active Expired - Lifetime
- 2003-08-19 JP JP2004530220A patent/JP4583174B2/ja not_active Expired - Fee Related
- 2003-08-19 MY MYPI20033143A patent/MY137053A/en unknown
- 2003-08-19 ES ES03792388T patent/ES2295682T3/es not_active Expired - Lifetime
- 2003-08-19 BR BR0313676-0A patent/BR0313676A/pt not_active IP Right Cessation
- 2003-08-19 EP EP03792388A patent/EP1539712B1/en not_active Expired - Lifetime
- 2003-08-19 KR KR1020057002813A patent/KR20050058367A/ko not_active Application Discontinuation
- 2003-08-19 DK DK03792388T patent/DK1539712T3/da active
- 2003-08-19 AT AT03792388T patent/ATE377591T1/de active
- 2003-08-19 AR ARP030102997A patent/AR041016A1/es unknown
- 2003-08-19 DE DE60335151T patent/DE60335151D1/de not_active Expired - Lifetime
- 2003-08-19 OA OA1200500052A patent/OA12910A/en unknown
- 2003-08-19 WO PCT/EP2003/009217 patent/WO2004018433A1/en active IP Right Grant
- 2003-08-19 SI SI200331088T patent/SI1539712T1/sl unknown
- 2003-08-19 AT AT07119063T patent/ATE489369T1/de not_active IP Right Cessation
- 2003-08-19 EA EA200500392A patent/EA010130B1/ru not_active IP Right Cessation
- 2003-08-19 PT PT03792388T patent/PT1539712E/pt unknown
- 2003-08-19 EA EA200700934A patent/EA012703B1/ru not_active IP Right Cessation
- 2003-08-19 PE PE2003000839A patent/PE20040898A1/es not_active Application Discontinuation
-
2005
- 2005-01-27 IL IL16655205A patent/IL166552A0/xx unknown
- 2005-02-01 ZA ZA200500913A patent/ZA200500913B/xx unknown
- 2005-02-18 EC EC2005005613A patent/ECSP055613A/es unknown
- 2005-03-07 MA MA28132A patent/MA27428A1/fr unknown
- 2005-03-17 IS IS7749A patent/IS7749A/is unknown
- 2005-03-18 NO NO20051451A patent/NO20051451D0/no not_active Application Discontinuation
- 2005-11-29 HK HK05110876A patent/HK1079193A1/xx not_active IP Right Cessation
-
2007
- 2007-08-27 IL IL185549A patent/IL185549A0/en unknown
-
2008
- 2008-01-31 CY CY20081100115T patent/CY1107871T1/el unknown
-
2009
- 2009-10-21 US US12/582,861 patent/US20100041654A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200700934A1 (ru) | Производные пиримидина и их применение в качестве модуляторов cb2 | |
ATE345329T1 (de) | Pyridinderivate als modulatoren des cb2-rezeptors | |
TW200611695A (en) | Pyrrolopyridine derivatives | |
UA83311C2 (en) | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | |
EA200501430A1 (ru) | Лиганды каннабиноидных рецепторов и их применение | |
EA200700489A1 (ru) | Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств | |
BG66084B1 (bg) | Циклопентаноиндоли, състави,съдържащи такива съединения и използването им | |
EA200501771A1 (ru) | Лиганды каннабиноидных рецепторов и их применения | |
TW200608966A (en) | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | |
NO20063064L (no) | Ny anvendelse av peptidforbindelser for behandling av sentralneurotisk smerte | |
MXPA05011922A (es) | Ligandos del receptor de cannabinoides y sus usos. | |
EA200700035A1 (ru) | Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders | |
NO20052028L (no) | Pyridinderivater som CB2 reseptor modulatorer | |
DK1725536T3 (da) | Imidazolin-derivater med CB1-antagonistisk aktivitet | |
RS20080246A (en) | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | |
EA200900900A1 (ru) | Производные замещенных 3-фенил-1-(фенилтиенил)пропан-1-онов и 3-фенил-1-(фенилфуранил)пропан-1-онов, их получение и применение | |
ATE407119T1 (de) | Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors | |
ATE340785T1 (de) | 2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren | |
SE9901077D0 (sv) | Novel use | |
TW200734335A (en) | Compounds | |
EA200600314A1 (ru) | Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях | |
EA200600115A1 (ru) | Производные 2-аминобензойной кислоты | |
DE60326348D1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
UA83142C2 (en) | 3-aminocyclopentane carboxyamidine as modulators of chemokine receptors | |
WO2007022938A3 (en) | Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |